TOTAL: $493.22M


Type Of

Number Of
Shares, Units
Or Warrants


Investors; Placement Agents; Details (Date)@ ($M)

Alliance Pharmaceutical Corp. (ALLP)

Debenture financing



Alliance received $10M from the sale of subordinated convertible debentures to a small group of investors, who have the option to purchase an additional $10M of debentures convertible into stock at $16 per share for four years after issuance (8/22)

Antisoma plc (UK; LSE:ASM)

Private Placement


#8.7 (US$13)

Antisoma raised #8.7M (US$13) by placing 7.68M shares at #1.17 per share, a discount of 8 percent to the July 26 closing price (7/27)

Aviron (AVIR)

Private placement



Aviron sold 262,200 shares to Acqua Wellington Asset Management LLC for an aggregate price of $8M, or $30.51 per share; the company did not pay any fees in connection with the transaction (8/8)

Bioject Medical Technologies Inc. (BJCT)

Equity financing



Bioject completed the final segment of a private equity financing with the sale of 150,000 shares at $7.88 per share, bringing the total financing to $10.5M net, represent- ing about 1.4M shares; Lone Pine Capital acted as the lead investor and five other investors participated (8/4)

Caliper Technologies Corp. (CALP)

Private placement of common stock



Caliper sold 2.3M shares at $48 per share, representing a discount to market price (8/30)

Cerus Corp. (CERS)

Private placement



Cerus raised $60M through the issuance of 1.2M shares at $50 per share (8/29)

CombiMatrix Corp., majority- owned affiliate of Acacia Research Corp. (ACRI)

Private equity financing



Investors included Acacia Research, Emerging Growth Management, JDS Capital, Oracle Partners, OrbiMed Advisors, SAC Capital Management, Seneca Capital and Wheatley Partners (8/3)

Coulter Pharmaceutical Inc. (CLTR)

Private placement



Coulter entered into an agreement to sell 1.655M shares at $21.625 per share, raising $35.8M; Pacific Growth Equities Inc. served as the placement agent (8/14)

CV Therapeutics Inc. (CVTX)

Common stock equity



CV received a commitment for up to $120M in common stock equity financing from Acqua Wellington North American Equities Fund Ltd.; CV may sell shares at its discretion and at a small discount to the market price over the next 28 months (8/8)

Derma Sciences Inc. (DSCIC)

Private financing



Derma concluded an agreement with three investment firms to sell $500,000 of the company's Series E units at $0.75 per unit; the units consist of one share and 1.1 warrant to purchase one share at $0.85 per share; the warrants expire July 18, 2005; purchasers included Kensington Capital Management LLC, Dolphin Offshore Partners and Redwood Asset Management (8/23)

Genelabs Technologies Inc. (GNLB)

Equity financing



Genelabs sold 779,271 shares to Acqua Wellington North American Equities Fund Ltd. for $3.99 per share; the company did not pay any fees in connection with the transaction (8/9)

Immunex Corp. (IMNX)

Shelf registration



Immunex filed for a shelf registration to sell up to 70M shares, 20M from the comp- any and 50M from American Home Products Corp., which holds 283.9M shares; terms will be determined at the time of the offering (8/9)

Incara Pharmaceuticals Corp. (INCR)

Equity financing facility



Incara entered into a definitive agreement with Torneaux Fund Ltd. to sell stock over 15 months; the amount of the investment is dependent on Incara's stock price and is ex- pected to exceed $3M, but is capped at $18.9M (8/18)

Interferon Sciences Inc. (OTCBB:IFSC)

Private placement of units



Interferon raised $7.7M from the sale of 11.64 units, which each contain one share of common stock and a warrant, exercisable until April 2005, to purchase one share at $1.50 (8/8)

InterMune Pharmaceuticals Inc. (ITMN)

Private placement of stock



InterMune raised $76M through a private placement of 2M shares at $38 per share; Prudential Vector Healthcare Group was the lead placement agent; co-placement agents were Lehman Brothers and UBS Warburg LLC (8/17)

Magainin Pharmaceuticals Inc. (MAGN)

Private placement



Magainin sold 4.1M shares at $3 per share, raising $12.4M; both existing and new in- vestors participated, including the State of Wisconsin Investment Board; Paramount Capital Inc. was financial adviser (8/11)

Matritech Inc. (NMPS)

Equity financing



Matritech entered into an agreement with Acqua Wellington North American Equities Fund Ltd. to sell over 14 months up to 2.45M shares that are part of a shelf registration; the shares may be sold at a small discount to market and the total investment is dependent on the company's stock price (8/24)

Myriad Genetics Inc. (MYGN)

Equity placement



Myriad received $22M in a direct equity placement with Acqua Wellington North American Equities Fund Ltd.; the 175,000 shares were sold at a small discount to the market price (8/29)

NeoRx Corp. (NERX)

Private placement



NeoRx sold 2.45M shares to institutional investors led by Lone Pine Capital LLC, Capital Research and Management Co., and Deerfield Management, raising $36M in net proceeds; following the offering, the company has 26M shares outstanding; Adams, Harkness & Hill Inc. acted as placement agent(8/29)

NexMed Inc.(NEXM)

Private equity placement



NexMed sold 2.008M shares, raising $16.68M; investors paying $18 per unit received two shares at $9 per share and one warrant to purchase one share at $13.50; investors paying $16.54 per unit received two shares at $8.27 per share and one warrant to purchase 0.7 share at $13.50; all warrants may be exercised over the next 18 months; investors included Capital Research and Management Co. and a mutual fund managed by a major investment firm; AmeriCal Securities Inc. acted as the placement agent (8/2)

NexMed Inc. (NEXM)

Private equity placement



NexMed sold an additional 1.13M shares, raising an additional $10.17M; investors paid $18 per unit and received two shares at $9 per share and one 18-month warrant to purchase one share at $16.20 per share; AmeriCal Securities Inc. and Shannon Limited acted as placement agents (8/9)

Oxford Biomedica plc (UK; LSE:OXB)

Private placement of ordinary shares


#8.5 (US$12.8)

Oxford raised #8.5M through the issuance of 14.6M ordinary shares at 60 pence per share (8/10)

Paracelsian Inc. (OTC:PRLN)

Private equity investment



Paracelsian received an equity investment of $0.5M and also issued warrants that could result in an additional investment of $1.5M by Dec. 31 if the warrants are exercised in full (8/10)

StemCells Inc. (STEM)

Private placement



StemCells completed a $4M common stock financing, receiving $3M at closing and will receive $1M more upon effectiveness of a reg- istration statement covering shares owned by the investment fund; the fund purchased the stock at $4.33 per share and will be entitled to receive additional shares on eight dates; the fund also has the option for 12 months to purchase up to $3M of additional common stock (8/7)

Syn X Pharma Inc. (CDNX:SYY

Private placement of special warrants


C$5.8 (US$3.9M)

Each warrant will be exercisable into one common share and one common share purchase warrant, which has a term of two years and entitles the holder to purchase one common share at C$4 in the first year and C$4.25 in the second year; 50 percent of proceeds go to Syn X and 50 percent will go in escrow pending the comp-any's achievement of two of six milestones; Octagon Capital Corp. and Thomson Kernaghan & Co. Ltd. led the placement (8/16)

Vion Pharmaceuticals Inc. (VION)

Exercise of purchase options



Holders of Vion's remaining 113,333 unit purchase options exercised them, giving the company $2.76M and resulting in the issuance of 494,816 shares; Vion now has 25.96M shares outstanding (8/14)

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
* Non-U.S. currencies converted at the exchange rate on the date of the announcement.
@ Dates refer to the date of the press release.
ASX = Australian Stock Exchange
LSE = London Stock Exchange
TSE = Toronto Stock Exchange
VSE = Vancouver Stock Exchange
OTC BB = Over The Counter Bulletin Board

No Comments